Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

259.34 +13.00 (+5.28%)
Streaming Delayed Price Updated: 1:44 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Insulet (PODD) Shares Skyrocket, What You Need To Know
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 5.6% in the afternoon session after the company posted strong fourth-quarter 2025 financial results that beat Wall Street's... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings... 
Via MarketMinute
Topics Earnings
Insulet Corp. (NASDAQ:PODD) Reports Strong Q4 Earnings Beat Amid Mixed 2026 Guidance ↗
Via Chartmill
Topics Earnings
Insulet Corp (NASDAQ:PODD): A Prime GARP Candidate in Diabetes Care ↗
Via Chartmill
Insulet Corp (NASDAQ:PODD) Matches Key Growth Rules in Navellier's "Little Book" Strategy ↗
Via Chartmill
Insulet Corp (NASDAQ:PODD) Passes Key Growth Screen with Strong Momentum ↗
Via Chartmill
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 31.2% year on year to $783.8 million. The company expects... 
Via StockStory
News headline image
Insulet Reports Fourth Quarter and Full Year 2025 Results
From Insulet Corporation
Via Business Wire
News headline image
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting earnings this Wednesday morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
News headline image
3 Profitable Stocks for Long-Term Investors
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting... 
Via StockStory
News headline image
2 Cash-Producing Stocks with Impressive Fundamentals and 1 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
From Insulet Corporation
Via Business Wire
News headline image
2 S&P 500 Stocks to Research Further and 1 Facing Challenges
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Which S&P500 stocks are moving on Friday? ↗
Via Chartmill
News headline image
1 Safe-and-Steady Stock with Impressive Fundamentals and 2 We Find Risky
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Is Insulet (PODD) the Future of Diabetes Management? ↗
Join us as we evaluate Insulet's potential in the diabetes management market. With a unique product offering and strong growth, could this stock be your next big investment? 
Via The Motley Fool
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
Precision Medicine and the Tubeless Revolution: An In-Depth Look at Insulet Corporation (PODD)
Today’s Date: January 9, 2026 Introduction In the rapidly evolving landscape of medical technology, few companies have managed to fundamentally reshape a multi-decade standard of care as successfully... 
Via PredictStreet
Topics Economy Product Recall World Trade
News headline image
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
From Insulet Corporation
Via Business Wire
Which S&P500 stocks are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
3 Healthcare Stocks with Exciting Potential
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their... 
Via StockStory
Topics Stocks
News headline image
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health
From Insulet Corporation
Via Business Wire
News headline image
2 Mid-Cap Stocks to Own for Decades and 1 That Underwhelm
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Topics Artificial Intelligence
News headline image
Insulet Corp (NASDAQ:PODD) Presents a Classic Growth at a Reasonable Price (GARP) Case ↗
Insulet Corp (PODD) exemplifies Growth at a Reasonable Price (GARP) with strong earnings growth, solid financials, and a valuation justified by its sector and future potential. 
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.